◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksKRYS › Operating Income

Krystal Biotech Inc (KRYS) Operating Income 2016–TTM

DATA UPDATED 2026-09-19

Krystal Biotech Inc annual operating income for fiscal TTM was $197 million, an increase of 22.4% from $161 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

KRYS Annual Operating Income

Operating Income (annual)TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating Income (EBIT)$197M$161M$66M($110M)($145M)($68M)($33M)($22M)($12M)($5M)($1M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KRYS Quarterly Operating Income

Operating Income (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Operating Income (EBIT)$58M$54M$44M$41M$39M$36M$41M$22M$9M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

More KRYS metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All KRYS financial statements → Interactive KRYS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.